CGNX heads into its Q1 earnings call on May 7 with the stock up nearly 10% on the week and options sentiment at its most bullish reading of the year.
The options signal is the standout this week. The put/call ratio has collapsed to 0.14 — more than three standard deviations below its 20-day average of 0.18, and the lowest reading in the past 52 weeks. That is an unusually aggressive tilt toward calls. It is consistent with the price action: the stock has added 20% over the past month and 4.5% in the last session alone, closing at $58.83. The setup reads less like hedging ahead of a catalyst and more like outright optimism going into the print.
Short interest tells a more cautious structural story, though it is far from extreme. Bears have been rebuilding modestly — SI has climbed about 26% over the past month to around 2.9% of the free float, roughly 4.9 million shares. That is a meaningful directional shift, but the absolute level remains low. Availability in the lending market is abundant, with borrowing costs running just 0.47% annually and borrow utilization near 4% — well below the 52-week peak of 9.5%. There is no squeeze pressure here. The short side is adding exposure, not trapped.
The Street's direction of travel has been mostly upward, though it fractured slightly ahead of earnings. Goldman Sachs raised its target to $68 in February and holds a Buy. Barclays has twice lifted its target, most recently to $64, keeping Overweight. JP Morgan upgraded from Underweight to Neutral in March. The one recent exception: Truist trimmed its target to $50 from $52 on April 20, maintaining Hold — a modest downward nudge but not a directional reversal. The consensus mean target is $65.50, about 11% above the current price. Valuation has expanded alongside the rally; the trailing P/E is now above 43x and EV/EBITDA near 35x. The 12-month forward EPS growth estimate ranks in the 94th percentile of the universe — the bull case rests squarely on a recovery in machine vision demand.
That bull case is built on Cognex's February earnings beat, when the stock surged 37% in a single session after revenues of $277 million came in well above guidance, with EBITDA growing 67% year-on-year. The bear case centres on automotive exposure — roughly 22% of 2024 sales — where project deferrals and European weakness have dragged on the industrial automation cycle. The most recent earnings print, on April 29, produced a more modest 3.3% gain. The two prior results generated a 37% one-day surge and a 2.7% decline respectively. The reaction range has been wide.
T. Rowe Price added over 1.2 million shares in the quarter to March, a notable add at roughly 3.2% of shares. Geode Capital added 843,000 shares. Vanguard and BlackRock, the two largest holders at 11% and 9.7% respectively, both added modestly. The institutional picture is constructive but not a concentrated bet. Insider activity has been limited to routine sells and awards at the director level, with no C-suite purchases in recent months.
What to watch on May 7 is whether management's commentary on automotive and consumer electronics demand supports the earnings recovery thesis — or whether guidance reflects the same order-deferral pattern the bear case has flagged.
See the live data behind this article on ORTEX.
Open CGNX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
